Abstract
AbstractResearch conducted during infectious disease outbreaks or pandemics can be crucial to control or ameliorate their consequences, but scientists are confronted with significant ethical questions about how to conduct research in such contexts. This chapter examines foundational ethical questions and considerations undergirding the research enterprise in pandemic contexts, including whether pandemics necessitate deviations from ethical and scientific standards for research, how research priorities are and ought to be set during pandemics, the ethics of conducting research alongside pandemic response efforts, and how pandemic research ought to be governed and coordinated. Scientists may have only a brief interval to understand the disease and develop medical countermeasures, and social pressures to produce fast results may seem overwhelming. Despite these challenges, this does not justify relaxing fundamental ethical or scientific standards, although there is scope for accelerating procedural requirements. Even during a pandemic, provision of most biomedical research funding by high-resource countries can influence the directions and results of research, leading to interventions that are more applicable in resource-rich than in resource-poor countries. The World Health Organization and other institutions are trying to correct or at least reduce these discrepancies. Biomedical research and health care response to a pandemic need not be rivals for funding support. The 2014 Ebola and 2019 COVID-19 experiences have demonstrated that the two can work synergistically. Both medical care and research responses are integral to our defenses against emerging or re-emerging infectious disease. Finally, the COVID-19 pandemic has made clear the need for changes in global architecture for pandemic response. The scientific and organizational adaptations required must be guided by ethical principles, such as the need to reduce the glaring inequities between high-income and low-income settings across the world as well as within countries. Preparing for the next pandemic will require a blueprint to accelerate the organization, coordination, and conduct of critical research and development.
Publisher
Springer International Publishing
Reference98 articles.
1. Adebamowo C, Bah-Sow O, Binka F, Bruzzone R, Caplan A, Delfraissy J-F, et al. Randomised controlled trials for Ebola: practical and ethical issues. Lancet. 2014;384(9952):1423–4.
2. Alirol E, Kuesel AC, Guraiib MM, de la Fuente-Núñez V, Saxena A, Gomes MF. Ethics review of studies during public health emergencies—the experience of the WHO ethics review committee during the Ebola virus disease epidemic. BMC Med Ethics. 2017;18(1):43. https://doi.org/10.1186/s12910-017-0201-1.
3. Alliance for Accelerating Excellence in Science in Africa. The Alliance for Accelerating Excellence in Science in Africa (AESA). 2021. https://www.aasciences.africa/aesa. Accessed 7 Dec 2021.
4. Andersen KG, Shapiro BJ, Matranga CB, Sealfon R, Lin AE, Moses LM, et al. Clinical sequencing uncovers origins and evolution of Lassa virus. Cell. 2015;162(4):738–50. https://doi.org/10.1016/j.cell.2015.07.020.
5. AVAC. Essential principles & practices for GPP compliance: engaging stakeholders in biomedical research during the era of COVID-19. New York: Global Advocacy for HIV Prevention (AVAC); 2021.